No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 27486112.
- Also identified by PMC identifier 6276897.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Postmarketing cases of hepatitis B virus (HBV) reactivation during hepatitis C treatment have been reported. We analyzed serum samples from patients in a clinical trial of ledipasvir-sofosbuvir in Taiwan and Korea. Of the 173 patients enrolled, 103 (60%) had been previously infected with HBV. None showed evidence of HBV reactivation.
Medical subject headings
- Antiviral Agents
- Benzimidazoles
- Fluorenes
- Hepatitis B
- Hepatitis B virus
- Hepatitis C
- Sofosbuvir
- Virus Activation